Sidra Medicine reports successful use of setmelanotide in rare childhood hypothalamic obesity cases

QATAR—Qatar’s Sidra Medicine, part of the Qatar Foundation, has published a detailed case report in Frontiers in Endocrinology describing the successful treatment of severe acquired hypothalamic obesity in a young child.

The report highlights how a targeted, mechanism-based approach helped manage a rare and complex form of obesity that developed after severe brain injury in infancy.

The case adds to growing clinical evidence that precision medicine can play a critical role in treating rare pediatric endocrine disorders where conventional weight management strategies are often ineffective.

 Brain injury and the development of hypothalamic obesity

The child developed hypothalamic obesity following a serious brain infection during the neonatal period, which led to inflammation, meningoencephalitis, and later brain abscess formation.

This condition disrupted the hypothalamus, the brain region responsible for regulating hunger, satiety, and energy balance.

As a result, the child experienced uncontrolled appetite and rapid weight gain that could not be managed through standard dietary or lifestyle interventions.

Clinicians identified that the underlying issue was neurological rather than behavioral, which guided the next phase of care.

Targeted treatment with Setmelanotide

Led by Professor Khalid Hussain, Senior Consultant in Pediatric Endocrinology at Sidra Medicine, the medical team introduced Setmelanotide, a melanocortin-4 receptor (MC4R) agonist that acts on appetite-regulating pathways in the brain.

The treatment decision followed extensive multidisciplinary review, as the medication was not originally approved for use in such a young child or for acquired hypothalamic obesity linked to inflammatory brain injury.

Careful, ethical, and clinical approvals were required before therapy could begin.

Treatment started when the child was 22 months old and was introduced gradually with close monitoring to ensure safety and effectiveness.

Clinical improvements and patient outcomes

Following initiation of therapy, clinicians observed a rapid reduction in excessive hunger, along with gradual stabilization of weight gain.

Over time, the child showed broader health improvements, including better liver function, improved cholesterol levels, reduced sleep apnea symptoms, enhanced mobility, and increased daily activity and engagement.

According to Dr. Hajar Dauleh, Endocrinology Specialist at Sidra Medicine, these improvements became more pronounced as the treatment was carefully adjusted over time based on the child’s response.

Multidisciplinary care and clinical significance

Dr. Ahmed Al Hammadi, Chair of Pediatric Medicine at Sidra Medicine, noted that the case underscores the importance of coordinated, multidisciplinary care in managing complex pediatric conditions.

The child’s treatment involved specialists across endocrinology, neurology, pulmonology, gastroenterology, ENT, intensive care, pharmacy, and rehabilitation services.

Although Setmelanotide has previously shown benefits in certain genetic forms of obesity, this case is believed to be the youngest reported use of the drug in acquired hypothalamic obesity linked to inflammatory brain injury.

The findings have been published in a case report titled “Effect of Setmelanotide Treatment in a Young Patient with Acquired Hypothalamic Obesity Following Escherichia coli Sepsis and Meningoencephalitis with Brain Abscess.”